Comparing Microneedling and Injectable Platelet Rich Fibrin to Hyaluronic Acid In Papilla Reconstruction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

EARLY_PHASE1

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-24

Study Completion Date

2026-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized split-mouth clinical trial aims to compare the clinical effectiveness of microneedling combined with injectable platelet-rich fibrin (i-PRF) versus hyaluronic acid (HA) gel injection in the reconstruction of Class I interdental papilla loss. The study hypothesizes that MN + i-PRF will yield greater papillary regeneration, offering a minimally invasive, biologically active alternative to traditional surgical approaches for soft-tissue esthetic rehabilitation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hydroxyapetite Nanoparticles, Tricalcium Phosphate Nanoparticles, and PRF for Treatment of Gingival Recession

NCT06016894

Periodontitis

COMPLETED NA

Clinical Evaluation of Hyaluronic Acid and Platelet Rich Fibrin Injection Efficacy in Interdental Papilla Reconstruction

NCT06314256

Interdental Papilla Loss

COMPLETED PHASE4

Efficacy of HA Gel Injection Versus Multilayer (L-PRF) in the Interdental Papilla Reconstruction

NCT05953896

Gingival Papillary Cratering

COMPLETED NA

Impact of Microneedling on the Gingival Tissue Surrounding Implant Supported Fixed Restoration.

NCT07294287

Gingiva Dental Implants

ACTIVE_NOT_RECRUITING NA

A Modern, Non-surgical Method for Treating Papillary Deficiencies is the Use of Hyaluronic Acid, Which Have Demonstrated Encouraging Outcome. Subperiosteal Hyaluronic Acid Injection Overlay Technique with the Idea of Merging Hyaluronic Acid Injection with Surgical Intervention to Reconstruct Idp

NCT06889311

Interdental Papillae Reconstruction Hyaluronic Acid

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Papilla Reconstruction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HA

Hyaluronic Acid Filler

Group Type EXPERIMENTAL

Hyaluronic Acid (HA)

Intervention Type OTHER

Filler

iPRF

Group Type ACTIVE_COMPARATOR

Injectable Platelet Rich Fibrin

Intervention Type BIOLOGICAL

Injectable Platelet Rich Fibrin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Injectable Platelet Rich Fibrin

Intervention Type BIOLOGICAL

Hyaluronic Acid (HA)

Filler

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Plaque index \<1
* Gingival index \<1
* Class I papillary loss (Nordland and Tarnow classification)
* Probing depth ≤4 mm at the test site
* Inter-proximal bone crest distance ≤7 mm from the contact point.

Exclusion Criteria

* Pregnancy
* Lactation
* Uncontrolled systemic diseases (e.g., diabetes)
* Anticoagulant therapy
* Recent radiotherapy
* Orthodontic treatment
* Midline diastema
* High frenum attachment
* Class II/III papillary loss.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No